The COVID-19 pandemic has had a profound impact on global health, economies, and societies. Globally, as of 29 March 2023, there have been more than 761 million confirmed cases of COVID-19, including more than 6 million deaths, reported to WHO. In the face of this unprecedented crisis, scientists around the world have been working tirelessly to understand the virus, develop effective treatments and vaccines, and mitigate its impact. SBS Genetech, a leading Chinese life science company, has been at the forefront of this effort, providing innovative and reliable products worldwide that have enabled ground-breaking research on the virus.

In this article, we will review four recent studies that have made significant contributions to the fight against COVID-19, all of which have relied on products from SBS Genetech. We will discuss the impact of these studies, their relevance to current and future pandemics, and the role that SBS Genetech has played in empowering them.

The first study titled "Mitochondrial regulation of acute extrafollicular B-cell responses to COVID-19 severity" was published in Clinical and Translational Medicine (impact factor: 8.554) in September 2022. The study, led by Dr. Chen Zhihua from the University of Hong Kong, China, investigated the role of mitochondrial dysfunction in the development of severe COVID-19. The researchers found that patients with severe COVID-19 had significantly impaired mitochondrial function, which led to abnormal B-cell responses and the production of autoantibodies. The study also identified a novel autoantibody, SSA/Ro60274-290, which was synthesized by SBS Genetech and used for autoantibody detection. This study sheds light on the complex pathophysiology of COVID-19 and opens up new avenues for therapeutic intervention.

The second study titled "Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples" was published in Scientific Reports (impact factor: 4.997) in March 2022, focused on the development of a portable real-time colorimetric LAMP device for rapid quantitative detection of nucleic acids in crude samples. Led by Dr. Gizeli Evangelia from Foundation for Research and Technology-Hellas, Greece, the study demonstrated the efficacy of the device in detecting SARS-CoV-2 RNA in clinical samples. The study utilized Bst DNA/RNA Polymerase from SBS Genetech in the mix, which enabled highly sensitive and specific detection of the virus. This study has important implications for the development of rapid diagnostic tools for COVID-19 and other infectious diseases.

The third study titled "Visualized RNA detection of SARS-CoV-2 in a closed tube by coupling RT-PCR with nested invasive reaction" published in Analyst (impact factor: 5.227) in January 2023, developed a closed-tube PCR method for visualized RNA detection of SARS-CoV-2. Led by Dr. Zhou Guohua from the Nanjing Medical University, China, the study utilized a nested invasive reaction and PCR mixture from SBS Genetech to achieve highly specific and sensitive detection of the virus. This method eliminates the need for post-PCR processing and greatly reduces the risk of contamination, making it a highly efficient and reliable diagnostic tool for COVID-19.

Finally, the last study titled "Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors" published in Biomedicine & Pharmacotherapy (impact factor: 7.419) in January 2023, reported the discovery of teicoplanin derivatives that can block spike protein-mediated viral entry and serve as pan-SARS-CoV-2 inhibitors. This study was carried out with a global collaboration with the joint effort of Dr. Cen Shan from Chinese Academy of Medical Sciences, China, and Dr. Liang Chen from Jewish General Hospital, Canada. In this article, Spike-D614G, which is known to enhance viral entry, was generated with the Muta-Direct Site-Directed Mutagenesis Kit from SBS genetech. This study provides new insights into potential therapeutic targets for COVID-19 and future coronavirus outbreaks.

Taken together, these four studies highlight the vital role that SBS Genetech plays in the fight against COVID-19. By providing high-quality products and services, the company has empowered researchers around the world to make significant contributions to the scientific community's understanding of this virus. The products and technologies developed by SBS Genetech have not only helped to advance our knowledge of COVID-19 but also have the potential to transform the landscape of diagnostic and therapeutic approaches for future pandemics.

As the world continues to grapple with the ongoing COVID-19 pandemic, the importance of scientific research and development has never been more apparent. SBS Genetech has demonstrated a steadfast commitment to advancing the field of life sciences and supporting scientists in their efforts to combat this devastating virus. Through collaborations with researchers and institutions worldwide, SBS Genetech has contributed to the scientific community's collective knowledge and understanding of COVID-19, paving the way for innovative approaches to diagnosis and treatment.

In conclusion, the global impact of the COVID-19 pandemic has been devastating, but the scientific community's response has been nothing short of extraordinary. The four studies highlighted in this article demonstrate the crucial role that SBS Genetech plays in this response. By providing the tools and technologies necessary for researchers to investigate the virus and develop effective treatments, SBS Genetech has made significant contributions to the fight against COVID-19. As the world continues to confront the ongoing challenges posed by this pandemic and future health crises, it is clear that companies like SBS Genetech will be at the forefront of the scientific community's efforts to protect public health and promote global well-being.